Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Bristol-Myers Squibb Dividend Announcement
• Bristol-Myers Squibb announced a quarterly dividend of $0.60 per ordinary share which will be made payable on 2024-11-01. Ex dividend date: 2024-10-04
• Bristol-Myers Squibb annual dividend for 2024 was $2.40
• Bristol-Myers Squibb annual dividend for 2023 was $2.28
• Bristol-Myers Squibb's trailing twelve-month (TTM) dividend yield is 4.33%
• Bristol-Myers Squibb's payout ratio for the trailing twelve months (TTM) is -66.20%
• Bristol-Myers Squibb's dividend growth over the last five years (2018-2023) was 7.34% year
• Bristol-Myers Squibb's dividend growth over the last ten years (2013-2023) was 2.62% year
Bristol-Myers Squibb Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-10-04 | $0.60 | quarterly | 2024-11-01 |
2024-07-05 | $0.60 | quarterly | 2024-08-01 |
2024-04-04 | $0.60 | quarterly | 2024-05-01 |
2024-01-04 | $0.60 | quarterly | 2024-02-01 |
2023-10-05 | $0.57 | quarterly | 2023-11-01 |
2023-07-06 | $0.57 | quarterly | 2023-08-01 |
2023-04-06 | $0.57 | quarterly | 2023-05-01 |
2023-01-05 | $0.57 | quarterly | 2023-02-01 |
2022-10-06 | $0.54 | quarterly | 2022-11-01 |
2022-06-30 | $0.54 | quarterly | 2022-08-01 |
2022-03-31 | $0.54 | quarterly | 2022-05-02 |
2022-01-06 | $0.54 | quarterly | 2022-02-01 |
2021-09-30 | $0.49 | quarterly | 2021-11-01 |
2021-07-01 | $0.49 | quarterly | 2021-08-02 |
2021-03-31 | $0.49 | quarterly | 2021-05-03 |
2020-12-31 | $0.49 | quarterly | 2021-02-01 |
2020-10-01 | $0.45 | quarterly | 2020-11-02 |
2020-07-02 | $0.45 | quarterly | 2020-08-03 |
2020-04-02 | $0.45 | quarterly | 2020-05-01 |
2020-01-02 | $0.45 | quarterly | 2020-02-03 |
2019-10-03 | $0.41 | quarterly | 2019-11-01 |
2019-07-03 | $0.41 | quarterly | 2019-08-01 |
2019-04-04 | $0.41 | quarterly | 2019-05-01 |
2019-01-03 | $0.41 | quarterly | 2019-02-01 |
2018-10-04 | $0.40 | quarterly | 2018-11-01 |
2018-07-05 | $0.40 | quarterly | 2018-08-01 |
2018-04-05 | $0.40 | quarterly | 2018-05-01 |
2018-01-04 | $0.40 | quarterly | 2018-02-01 |
2017-10-05 | $0.39 | quarterly | 2017-11-01 |
2017-07-05 | $0.39 | quarterly | 2017-08-01 |
2017-04-05 | $0.39 | quarterly | 2017-05-01 |
2017-01-04 | $0.39 | quarterly | 2017-02-01 |
2016-10-05 | $0.38 | quarterly | 2016-11-01 |
2016-06-29 | $0.38 | quarterly | 2016-08-01 |
2016-03-30 | $0.38 | quarterly | 2016-05-02 |
2015-12-30 | $0.38 | quarterly | 2016-02-01 |
2015-09-30 | $0.37 | quarterly | 2015-11-02 |
2015-07-01 | $0.37 | quarterly | 2015-08-03 |
2015-04-01 | $0.37 | quarterly | 2015-05-01 |
2014-12-30 | $0.37 | quarterly | 2015-02-02 |
2014-10-01 | $0.36 | quarterly | 2014-11-03 |
2014-07-01 | $0.36 | quarterly | 2014-08-01 |
2014-04-02 | $0.36 | quarterly | 2014-05-01 |
2013-12-31 | $0.36 | quarterly | 2014-02-03 |
2013-10-02 | $0.35 | quarterly | 2013-11-01 |
2013-07-02 | $0.35 | quarterly | 2013-08-01 |
2013-04-03 | $0.35 | quarterly | 2013-05-01 |
2013-01-02 | $0.35 | quarterly | 2013-02-01 |
Bristol-Myers Squibb Dividend per year
Bristol-Myers Squibb Dividend growth
Bristol-Myers Squibb Dividend Yield
Bristol-Myers Squibb current trailing twelve-month (TTM) dividend yield is 4.33%. Interested in purchasing Bristol-Myers Squibb stock? Use our calculator to estimate your expected dividend yield:
Bristol-Myers Squibb Financial Ratios
Bristol-Myers Squibb Dividend FAQ
Other factors to consider when evaluating Bristol-Myers Squibb as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Bristol-Myers Squibb stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Bristol-Myers Squibb's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Bristol-Myers Squibb publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Bristol-Myers Squibb distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Bristol-Myers Squibb are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Bristol-Myers Squibb sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Bristol-Myers Squibb distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Bristol-Myers Squibb declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Bristol-Myers Squibb's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Bristol-Myers Squibb's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.